Menu
Recruiting NCT04765098

Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

Phase II Interventional Glioblastoma Multiforme

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Tamoxifen, Etoposide.
Who it may be relevant to
Registry conditions: Glioblastoma Multiforme. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Randomized Controlled Trial of Tamoxifen Versus Etoposide for Patients With First Recurrence of Glioblastoma Multiforme

Overview

The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.

Interventions

  • Drug Tamoxifen
    Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously
  • Drug Etoposide
    etoposide 50mg/m2 daily

Primary outcome measures

  • 3 month progression-free survival [Time frame: 3 months]
Secondary outcome measures (4)
  • One-year progression-free survival [Time frame: 12 months]
  • Overall survival [Time frame: Median, 6-month, 1-year, and 2-year OS rates will be measured]
  • Health-related quality-of-life status [Time frame: Throughout study completion, up to 5 years.]
  • Adverse events [Time frame: Throughout the whole duration of the trial, up to 5 years]

Eligibility criteria

Inclusion criteria

  • Histologically proven GBM with progression after previous first line chemoradiotherapy with temozolomide.
  • Progression documented by MRI with at least one bi-dimensionally measurable target lesion with one diameter of at least 10 mm, visible on two or more axial slices 5 mm apart.
  • Not received radiotherapy within the three months before the diagnosis of progression.
  • Stable or decreasing dose of corticosteroids prior to randomization: corticosteroids (dexamethasone) should be given at the lowest dose needed to control symptoms arising from increased intracerebral edema.
  • ECOG performance 0-2 (Appendix 2).
  • Age from 18-65 years.
  • Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 72 hours prior to the first dose of study treatment. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes.
  • Patients of childbearing / reproductive potential should use adequate birth control methods, as defined by the investigator, during the study treatment period and for a period of 60 days after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.

Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.

  • Laboratory evaluation obtained within 7 days prior to randomization, with adequate function as defined below:
  • ANC ≥ 1.5 x 109/L
  • Platelets ≥ 100 x 109/L
  • Serum creatinine ≤ 1.5 times ULN
  • Total serum bilirubin ≤ 1.5 times ULN
  • ALT < 3 times ULN
  • AST < 3 times ULN
  • Alkaline phosphatase < 3 times ULN
  • Patient must understand and sign an informed consent prior to study registration.

Exclusion criteria

  • History of another malignancy or a concurrent malignancy (exceptions include patients who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ.
  • Uncontrolled hypertension (systolic blood pressure >150 mm Hg or diastolic blood pressure >100 mm Hg).
  • Any arterial or venous thrombosis up to 6 months before registration.
  • Evidence of recent hemorrhage on brain MRI.
  • Substantial cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (> New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Canada · 1 center
  • Cross Cancer Institute — Edmonton

Identifiers

NCT: NCT04765098 · IIT-0014

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗